Global Breast Cancer Diagnostics Market Company Profile and its Business Tactics & Demand Forecast 2022-2028
Size of the Breast Cancer Diagnostics Market
Zion Market Research Analyses that the global Breast Cancer Diagnostics market generated roughly USD 5.1 billion in revenue in 2020 and is projected to generate around USD 12.5 billion by 2028, expanding at a CAGR of nearly 8% from 2021 to 2028. The research provides an assessment and analysis of the worldwide and regional Breast Cancer Diagnostics market. The paper provides a thorough analysis of market competition, restraints, revenue forecasts, opportunities, changing market trends, and industry-verified data. The report contains historical data from 2018 to 2020 and revenue projections from 2021 to 2028. (USD Billion).
The market for Breast Cancer Diagnostics: Synopsis
Early diagnosis of cancer cells can reduce the number of fatalities caused by breast cancer in women. Numerous breast diagnostic procedures have been examined by researchers, including mammography, ultrasound, positron emission tomography, computed tomography, biopsy, and magnetic resonance imaging. However, these procedures have proven to be prohibitively expensive, time-consuming, and inappropriate for young women.
Therefore, it is of the utmost importance to develop diagnostic procedures for early detection of breast cancer tumors or masses. Utilizing a variety of indicators, researchers are concentrating on the development of biosensors for breast cancer detection. In addition to biomarkers and biosensors, researchers are exploring the functions of microwave imaging systems in order to employ them as diagnostic tools for breast cancer screening and early detection in the next years. According to the NCBI, in recent years physicians have prescribed microwave imaging techniques as a safe and cost-effective alternative to mammography for breast cancer diagnosis.
Request to Get Free PDF Report copy: https://www.zionmarketresearch.com/sample/breast-cancer-diagnostics-market
The market for Breast Cancer Diagnostics: Growth Drivers
In the future years, the breast cancer diagnostics market will expand due to a significant decline in breast cancer-related fatalities in nations such as the U.S. between 1975 and 2000 as a result of advances in breast cancer diagnostic and screening procedures. Survival rates of patients will grow as a result of earlier breast cancer screening, influencing market trends. In addition, discoveries in the fields of molecular biology and pharmacology will drive the growth of the breast cancer diagnostics market during the next few years by simplifying the development of innovative breast cancer treatment methods. With biomarker-based screening techniques such ELISA, radioimmunoassay, fluoroimmunoassay, and immunohistochemistry catering to the needs of breast cancer diagnostics, the market is expected to grow in the future years.
Furthermore, from 2021 to 2028, significant opportunities will be created for the breast cancer diagnostics business as a result of government initiatives that promote breast cancer screening and early detection for the purposes of treatment and cure. In the next years, the introduction of technologically advanced products, such as direct-to-consumer testing tools for early cancer diagnosis in patients, will contribute significantly to the growth of the breast cancer diagnostics market.
The global Breast Cancer Diagnostics Market is segmented as follows:
By Type
Imaging
Blood Tests
Genomic Tests
Biopsy
By Product
Platform-based
Instrument-based
By Region
North America
The U.S.
Canada
Europe
France
The UK
Spain
Germany
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC
South Africa
Rest of the Middle East & Africa
Regional Landscape
By 2028, North America will dominate the breast cancer diagnostics market expansion.
Large numbers of reputable breast cancer diagnostic centres in the U.S. and Canada are responsible for the region's market dominance over the predicted period. In addition, the availability of comprehensive diagnostic and screening infrastructure facilities in numerous North American nations would pave the way for the expansion of the breast cancer diagnostics market in the subcontinent. Increasing patient knowledge of breast cancer early detection will further influence market development in the region over the next decade.
Competitive Environment
In the report, Hologic Inc., Danaher Corporation, QIANGEN N.V., Koninklijke Philips N.V., F. Hoffmann-La Roche Limited, Argon Medical Devices, Inc., and BD are identified as key players impacting market revenue.
The following tests and methods are used to diagnose breast cancer:
Breast examination. Your doctor will examine both of your breasts and armpit lymph nodes for lumps and other abnormalities.
A mammogram is an X-ray image of the breast. Mammograms are routinely used for breast cancer screening. Your doctor may recommend a diagnostic mammography if a screening mammogram reveals an abnormality.
Ultrasound is used to obtain images of structures deep within the body using sound waves. Ultrasound can be used to evaluate if a new breast lump is a solid mass or a cyst filled with fluid.
Obtaining a sample of breast cells for analysis (biopsy): A biopsy is the only approach to definitively diagnose breast cancer. During a biopsy, your doctor extracts a sample of questionable tissue using a specialised needle instrument guided by X-ray or another imaging test. Typically, a small metal marker is left at the place within your breast so that it can be easily seen during further imaging examinations.
Experts analyse biopsy specimens in a laboratory to determine whether the cells are malignant. A biopsy sample is also evaluated to establish the type of breast cancer cells, the cancer's aggressiveness (grade), and the presence of hormone receptors or other receptors that may affect your treatment options.
Breast magnetic resonance imaging (MRI): An MRI machine uses a magnet and radio waves to produce images of your breast's interior. Before a breast MRI, a dye injection is administered. Unlike other imaging examinations, MRI images are created without the use of radiation.
ASKED QUESTIONS
Which significant factors will impact the growth of the Breast Cancer Diagnostics Market from 2021 to 2028?
In the future years, the breast cancer diagnostics market will expand as a result of a considerable decline in breast cancer-related fatalities in nations such as the United States between 1975 and 2000, which was caused by the ongoing advancement of breast cancer diagnostic & screening procedures. Increased patient survival rates resulting from earlier breast cancer identification will drive market trends.
Furthermore, discoveries in the fields of molecular biology and pharmacology for understanding breast cancer and thereby aiding the creation of innovative breast cancer treatment methods will drive market growth in the coming years. With biomarker-based screening techniques such as ELISA, radioimmunoassay, fluoroimmunoassay, and immunohistochemistry catering to breast cancer diagnostics demands, the market is expected to grow in the future years.
Furthermore, favourable government programmes supporting increased breast screening and diagnosis for early cancer detection for treatment and cure will generate profitable opportunities for the breast cancer diagnostics market from 2021 to 2028.
What will the Breast Cancer Diagnostics Market be worth between 2021 and 2028?
According to a report by Zion Market Research, the global Breast Cancer Diagnostics market generated roughly 5.1 (USD Billion) in revenue in 2020 and is projected to generate approximately 12.5 (USD Billion) by 2028, registering a CAGR of nearly 8% from 2021 to 2028.
Which region will significantly contribute to the value of the global Breast Cancer Diagnostics Market?
In the forecast timeframe, North America will contribute lucratively to the global market's income. Due to the large number of recognised breast cancer diagnostic facilities in the United States and Canada, the regional market is expanding. In addition, the availability of sophisticated diagnostic and screening infrastructure amenities in numerous North American countries would pave the way for the expansion of the breast cancer diagnostics market in the subcontinent. In the following decade, market growth in the region will be further influenced by a rise in patient awareness of breast cancer early detection.
Who are the key players driving the growth of the Breast Cancer Diagnostics Market?
Hologic Inc., Danaher Corporation, QIANGEN N.V., Koninklijke Philips N.V., F. Hoffmann-La Roche Limited, Argon Medical Devices, Inc., and BD are the leading market participants.
Facebook Conversations